Hon. Margaret M. Heckler 
March 12, 1984 
Page Two 
(3) What Is HHS's projection for FY '84 and FY '85 for the number of appli- 
cations It anticipates receiving for field scale releases? For commer- 
cial releases? 
(4) To the extent HHS Intends to review applications for field scale re- 
lease or release Into the environment for commercial purposes, has HHS 
or NIH conducted an analysis or developed a strategic plan for the 
Implementation of Its program? Has HHS or NIH developed a budget and 
workload analysis to Implement its program? (If so, I would appreciate 
receiving a copy of these documents). 
(5) How does HHS think that the talent and expertise in genetic engineering 
available on the RAC can best be utilized to assure that research 
progress and commercialization of biotechnology proceed in a timely 
fashion, while providing for appropriate review to insure public health 
and safety? Is additional legislation necessary for this purpose? 
I appreciate your attention to this request. If you have any questions, 
please contact Robert B. Nicholas, Staff Director/Counsel, or Dr. Morris Levin, 
LEGIS fellow, of the Investigations and Oversight Subcommittee staff at 
226-3636. 
Subcommittee on Investigations 
and Oversight 
AG/Ntk 
Enclosure 
cc: James B. Wyngaarden, Director 
National Institutes of Health 
9000 Rockv i I le Pike 
Bethesda, Maryland 20205 
[ 689 ] 
